Business
DiagnosTear Technologies Inc. Announces Results of AGM
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general meeting of shareholders (the "AGM") held today. Shareholders approved all matters recommended by management, including:Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn and John Sinclair as directors of the Company;The appointment
About this update from Diagnostear Technologies, Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general meeting of shareholders (the "AGM") held today. Shareholders approved all matters recommended by management, including:","length":349,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn and John Sinclair as directors of the Company;","length":166,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":166,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"The appointment of Doane Grant Thornton LLP., as the Company's auditors for the year ended December 31, 2025, and for the ensuing year; and","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approve and confirm the Company's "rolling 10%" equity incentive plan.","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":227,"olType":false},{"type":"text","content":"For further information, please contact:","length":40,"tagName":"p"},{"type":"text","content":"Dr. Shimon GrossChief Executive OfficerDiagnosTear Technologies Inc.Email: [email protected]: +972-523408550","length":120,"tagName":"p"},{"type":"text","content":"About DiagnosTear","length":17,"tagName":"p"},{"type":"text","content":"DiagnosTear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. DiagnosTear's TeaRx™ technology is a diagnostic platform intended for rapid, Point-of-Care Testing (POCT) of ophthalmic pathologies through multi-parameter analysis of non-invasively collected tear fluid. The first CE-IVD, and Israeli MoH-approved test based on the TeaRx™ platform is intended for diagnosis of Dry Eye Syndrome (DES TeaRxTM Dry Eye). This product is not FDA-cleared yet. Beyond DES, DiagnosTear is developing innovative tests based on the TeaRx™ platform for additional ophthalmic indications. Among others, DiagnosTear's pipeline includes TeaRx™ Red Eye: The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpeti...